Core Viewpoint - The biopharmaceutical vaccine concept stocks experienced a significant surge, with notable increases in share prices for several companies [1] Group 1: Stock Performance - Zhifei Biological and Watson Bio both saw their stock prices rise by over 10% [1] - Kangtai Biological, CanSino, and Baike Biological experienced increases of over 5% [1] - Other companies such as Hualan Vaccine, Bohui Innovation, and Junshi Biological also followed with gains [1]

Investment Rating - The industry investment rating is maintained as "Overweight" [1] Core Insights - In the first half of 2025, the number of clinical trial applications and market approvals for vaccines continues to grow rapidly, with 45 clinical trial applications and 12 market approvals accepted, representing a 58.3% year-on-year increase [3] - The vaccine industry is experiencing a phase of supply-demand imbalance, impacting overall performance, but there is a long-term focus on innovation and international expansion [8][24] - The industry is driven by three main factors: policy, demand, and technology, with a strong emphasis on innovative vaccines and technical upgrades [8][24] Summary by Sections Industry Performance - The vaccine sector saw a 3.61% increase last week, ranking second among 13 sub-sectors in the pharmaceutical industry [4] - The cumulative decline in the vaccine sector since the beginning of 2025 has narrowed to 6.18% [4] Market Review - The vaccine sector's PE (ttm) is 75.17X, with a year-on-year maximum of 76.07X and a minimum of 19.57X, indicating a significant valuation range [6] - The PB (lf) for the vaccine sector is 1.83X, with a maximum of 2.58X and a minimum of 1.62X over the past year [6] Investment Recommendations - The report suggests focusing on companies with strong research and innovation capabilities, particularly those with differentiated products, recommending companies like CanSino and Kanghua Biological [8][26] - The report emphasizes the importance of technical innovation and product differentiation as key competitive advantages in the vaccine industry [26]

证券代码：301207 证券简称：华兰疫苗 公告编号：2025-034 华兰生物疫苗股份有限公司 关于非独立董事辞任暨选举职工代表董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、关于非独立董事辞任并选举职工代表董事的情况 华兰生物疫苗股份有限公司（以下简称"华兰疫苗"或"公司"）于近日收到 公司非独立董事潘若文女士的书面辞任报告。因公司内部工作调整，潘若文女士申 请辞去公司第二届董事会非独立董事职务，并在此之后担任公司职工代表董事职务。 2025 年 7 月 8 日，公司召开职工代表大会，会议选举潘若文女士为公司第二届董事 会职工代表董事，任期自本次职工代表大会审议通过之日起至公司第二届董事会任 期届满之日止。 潘若文女士符合《公司法》《公司章程》规定的有关职工代表董事的任职资格 和条件。潘若文女士当选公司职工代表董事后，公司第二届董事会成员中兼任公司 高级管理人员以及由职工代表担任的董事人数总计未超过公司董事总数的二分之一， 符合相关法律法规的要求。 潘若文女士的简历详见附件。 附件： 二、备查文件 潘若文女士简历 公司职工代表大会决议。 特 ...

安徽承义律师事务所 关于 华兰生物疫苗股份有限公司 召开 2025 年第一次临时股东大会的 法律意见书 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司股东 会规则》等法律法规和其他规范性文件的要求，安徽承义律师事务所接受华兰生 物疫苗股份有限公司（以下简称"公司"）的委托，指派鲍金桥、万晓宇律师（以 下简称"本律师"）就公司召开 2025 年第一次临时股东大会（以下简称"本次股东 大会"）出具法律意见书。 一、本次股东大会召集人资格和召集、召开的程序 经核查，本次股东大会是由公司第二届董事会召集，公司已于 2025 年 6 月 21 日在中国证监会指定的信息披露网站和深圳证券交易所网站上披露了《关于 召开 2025 年第一次临时股东大会的通知》。本次股东大会的现场会议于 2025 年 7 月 8 日 13:30 在河南省新乡市华兰大道甲 1 号附 1 号公司办公楼会议室如期 召开。 安徽承义律师事务所 中国.合肥市政务区怀宁路 200 号栢悦中心 5 楼 邮编: 230022 电话（Tel）: （86-551）65609815 传真（Fax）: （86-551）65608051 网址（Webs ...

证券代码：301207 证券简称：华兰疫苗 公告编号：2025-033 华兰生物疫苗股份有限公司 2025年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1.本次股东大会未出现否决议案的情形。 2.本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1、本次股东大会的召开时间： 现场会议召开时间为：2025 年 7 月 8 日下午 13:30 网络投票时间：2025 年 7 月 8 日。其中通过深圳证券交易所交易系统进行网络 投票的具体时间为 2025 年 7 月 8 日上午 9:15—9:25,9:30—11:30 和下午 13:00— 15:00；通过深圳证券交易所互联网投票的具体时间为 2025 年 7 月 8 日 9:15 至 15:00 期间的任意时间。 2、会议召开地点：华兰生物疫苗股份有限公司（以下简称"公司"）办公楼会议 室 3、召集人：公司董事会 4、会议方式：现场投票、网络投票相结合的方式 5、现场会议主持人：董事长安康先生 6、本次股东大会的会议召集、召开程序符合有关法律、法 ...

Investment Rating - The industry investment rating is maintained at "Overweight" [2] Core Views - The report highlights the establishment of the first national vaccine inspection center in Beijing, expected to accelerate the market entry of innovative vaccines [3] - The draft of the Medical Security Law was presented, which may enhance the insurance coverage for vaccines during major infectious disease outbreaks [3] - The vaccine industry is currently facing performance pressure due to supply-demand imbalances, with a high proportion of Me-too products leading to intense competition and price declines [7][26] - Long-term focus on innovation and international expansion is recommended as key strategies for companies in the vaccine sector [7][28] Market Performance - The vaccine sector saw a 1.36% increase last week, with a cumulative decline of 9.84% since the beginning of 2025 [4][10] - The overall pharmaceutical sector experienced a 1.6% increase during the same period [4] Company Performance - Top-performing companies in the vaccine sector include Jindike, Kanghua Biological, and Liaoning Chengda, while underperformers include CanSino and Watson Biologics [5] Valuation Metrics - The vaccine sector's PE (ttm) is 72.25X, with a PB (lf) of 1.76X, indicating a slight increase in valuation metrics compared to previous periods [6] Investment Recommendations - The report suggests focusing on companies with strong R&D capabilities and innovative products, recommending Kanghua Biological and CanSino as potential investment opportunities [8][28]

Core Viewpoint - The company, Hualan Biological Engineering Inc., is revising its articles of association and related governance documents to comply with new regulations and improve corporate governance practices [1]. Summary by Sections Revision of Articles of Association - The company is amending its articles of association and related rules to align with the new Company Law and relevant regulations [1]. - Specific changes include the role of the chairman as the legal representative and the process for appointing a new legal representative within 30 days of resignation [2]. - The company can now provide financial assistance for acquiring its shares, with a limit of 10% of the total issued capital, subject to board approval [2]. Governance Procedures - Shareholders have the right to request the court to declare board resolutions invalid if they violate laws or regulations [3]. - Minor procedural flaws in meetings do not invalidate resolutions unless they have a substantial impact [4]. - Shareholders holding more than 5% of shares must report any pledging of their shares to the company [5]. Responsibilities of Directors and Shareholders - Directors and senior management must act in the best interests of the company and its shareholders, with specific duties outlined to prevent conflicts of interest [6][7]. - The company’s controlling shareholders and actual controllers are required to exercise their rights without harming the interests of the company or other shareholders [8]. Independent Directors - Independent directors must maintain their independence and are subject to specific qualifications and responsibilities to protect minority shareholders' rights [27][28]. - The company is required to evaluate the independence of its independent directors annually [27]. Committees and Decision-Making - The board of directors will establish various committees, including an audit committee, to oversee financial reporting and compliance [30]. - Major investment decisions must be reviewed by relevant experts and approved by the shareholders [24][30].

Meeting Information - The company will hold its first extraordinary general meeting of shareholders for 2025 on July 8, 2025, at 13:30 [1][2] - Shareholders can participate either in person or through a proxy, and online voting will be available via the Shenzhen Stock Exchange trading system [1][2] Voting Procedures - Shareholders must choose between on-site voting or online voting, with duplicate votes being invalidated [1][2] - The online voting will be available from 9:15 to 15:00 on July 8, 2025 [2] Attendance and Registration - All shareholders registered by the close of trading on July 3, 2025, are entitled to attend the meeting [2][5] - Registration procedures for different types of shareholders are outlined, including requirements for corporate and individual shareholders [6] Agenda Items - The meeting will review several proposals, including amendments to the company's articles of association and governance systems [5][11] - A special resolution requires approval from more than two-thirds of the voting rights held by attending shareholders [5] Proxy Voting - Proxy voting is allowed, and specific instructions must be provided by the shareholder to the proxy [8][11] - The company emphasizes that proxies do not need to be shareholders of the company [2][5]

证券代码：301207 证券简称：华兰疫苗 公告编号：2025-031 华兰生物疫苗股份有限公司 关于修订《公司章程》及制定、修订部分治理制度的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 华兰生物疫苗股份有限公司（以下简称"公司"）于2025年6月20日召开第二届董 事会第十五次会议，审议通过了《关于修订〈公司章程〉及其附件并办理工商变更 登记的议案》和《关于制定、修订公司部分治理制度的议案》，上述议案尚需提交 公司股东大会审议。现将有关情况公告如下： | | | 第二十二条 公司或者公司的子公司（包 括公司的附属企业）不得以赠与、垫资、 担保、借款等形式，为他人取得本公司或 | | --- | --- | --- | | | | 者其母公司的股份提供财务资助，公司实 | | | 第二十一条 公司或公司的子公司（包括公 | 施员工持股计划的除外。 | | | 司的附属企业）不得以赠与、垫资、担保、 | 为公司利益，经股东会决议，或者董 | | 3 | 补偿或贷款等形式对购买或者拟购买公司 | 事会按照本章程或者股东会的授权作出 | | | 股份的人提 ...

董事、高级管理人员任职薪酬、津贴管理制度 华兰生物疫苗股份有限公司 董事、高级管理人员任职薪酬、津贴管理制度 第一条 为客观反映华兰生物疫苗股份有限公司（以下简称"公司"）董事、高 级管理人员所付出的劳动，在公司决策过程中所承担的风险与责任，切实激励公 司董事、高级管理人员积极参与决策、管理与监督，提高公司的经营管理效益， 以更好的促进公司健康、持续发展，公司实行董事、高级管理人员任职薪酬、津 贴管理制度。根据《公司法》《上市公司治理准则》等法律、行政法规及《公司 章程》的有关规定，结合公司实际情况，制定本制度。 第二条 本制度适用于公司全体董事、高级管理人员。 1、独立董事津贴为每年人民币10万元，非独立董事不发放董事津贴。 公司董事会薪酬与考核委员会可以根据实际履职情况对独立董事薪酬 （津贴）进行调整。 2、公司高级管理人员的薪酬由基本薪酬和绩效薪酬构成，其中基本薪酬根 据高级管理人员的岗位价值、公司经营状况、市场薪酬水平及个人能力等因素 确定一套基本薪酬标准，基本薪酬不浮动，按月发放。绩效薪酬与公司利润完 成率、目标责任制考核结果挂钩，于每年考评工作结束后支付。 第三条 公司发放的薪酬和津贴为税前金额， ...